New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
06:33 EDTCYTRCytRx begins Phase 2 clinical trial with aldoxorubicin for Kaposi's sarcoma
CytRx has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposiís sarcoma. The primary objective of preliminary efficacy will be determined through evaluation of the size, number and nodularity of skin lesions, and the company will evaluate the level of aldoxorubicin uptake into lesions. CytRx plans to discuss a pathway for the registration of aldoxorubicin for KS with the FDA if the data are positive. The company expects to announce data from this Phase 2 clinical trial in Q2 2015.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
10:10 EDTCYTRHigh option volume stocks
High option volume stocks: HNT THOR QRVO CYTR CBRL MAS CHKP TUP NXPI VEDL
July 21, 2015
10:14 EDTCYTRHigh option volume stocks:
Subscribe for More Information
09:21 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
08:47 EDTCYTRCytRx 9.1M share Spot Secondary priced at $2.75
Subscribe for More Information
July 20, 2015
19:02 EDTCYTROn The Fly: After Hours Movers
Subscribe for More Information
16:02 EDTCYTRCytRx files to sell common stock, no amount given
Jefferies LLC is the sole book-running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use